Intraocular infiltration of Philadelphia chromosome-positive acute lymphoblastic leukemia diagnosed by polymerase chain reaction from the aqueous humor

A case report

Miki Hiracka, MD, PhD\(^a,^\ast\), Hiroshi Ohguro, MD, PhD\(^a\), Hiroshi Ikeda, MD, PhD\(^b\), Daisuke Furuya, MT, PhD\(^c\), Satoshi Takahashi, MD, PhD\(^d\)

Abstract

**Rationale:** Intraocular manifestation of hematopoietic tumors is rare and often difficult to distinguish from inflammation. We report a patient with acute lymphoblastic leukemia (ALL) who developed intraocular infiltration during the remission period.

**Patient concerns:** A 40-year-old man presented with hypopyon in his right eye. Three months later, extensive subretinal infiltration and the elevation of intraocular pressure were observed. Fourteen months prior to this, he had been diagnosed with Philadelphia chromosome-positive ALL, and had received chemotherapy and bone marrow transplantation that resulted in complete remission.

**Diagnosis:** The breakpoint cluster region-Ableson (BCR/ABL) chimera was detected by polymerase chain reaction (PCR) analysis in the patient’s aqueous humor. Additionally, a high expression of WT1 (Wilms tumor gene) mRNA in the aqueous humor was discovered. A bone marrow examination yielded a high expression of BCR/ABL fusion gene, and it was determined the patient had experienced a relapse of ALL.

**Interventions:** The dasatinib was administered orally to the patient.

**Outcomes:** The intraocular infiltration disappeared, and intraocular pressure was normalized.

**Lessons:** Intraocular infiltration in leukemia patients may be an indication of relapse regardless of systemic conditions. Analyzing mRNA expression of BCR/ABL and WT1 of ocular fluid in patients with hypopyon is beneficial in diagnosing topical relapses in leukemia.

**Abbreviations:** ALL = acute lymphoblastic leukemia, AML = acute myeloid leukemia, BCRA = best-corrected visual acuity, FISH = fluorescence in situ hybridization, IOP = intraocular pressure, MDS = myelodysplastic syndromes, MRI = magnetic resonance imaging, PCR = polymerase chain reaction, Ph+ALL = Philadelphia chromosome-positive ALL, WT1 = Wilms tumor gene.

**Keywords:** acute lymphoblastic leukemia, hypopyon, Philadelphia chromosome, polymerase chain reaction, Wilms tumor gene

1. Introduction

Hypopyon is the accumulation of infiltrating cells in the anterior chamber, and is a sign of uveitis. The 2 major causes of uveitis are autoimmune disease and infection, in both of which inflammatory cells are infiltrated in intraocular fluid. Occasionally, hypopyon is observed in malignant diseases such as hematologic malignant disease and retinoblastoma. The infiltrated cells in such instances contain malignant cells. Distinguishing whether the signs of hypopyon indicate inflammation or malignancy can be difficult.\(^{[1]}\) Ocular disorder caused by malignant disease is therefore referred to as a masquerade syndrome that mimics inflammation.\(^{[1]}\) The uveitis masquerade syndrome is commonly associated with hematologic malignancies. The major causes of uveitis masquerade syndrome are lymphoma and leukemia.\(^{[1,2]}\)

The ocular infiltration of malignancy is mainly diagnosed by cytologic examination followed by immunophenotyping using intraocular fluid such as the vitreous body or aqueous humor. Recently, it has been determined that the Wilms tumor gene (WT1) mRNA expression in blood and bone marrow is a prognostic marker in leukemia.\(^{[3]}\) However, the WT1 mRNA of the aqueous humor has never been examined.

In this report, we describe a case presenting with unilateral leukemic intraocular infiltration as an initial sign of acute lymphoblastic leukemia (ALL) relapse. The chimeric BCR/ABL gene in the aqueous humor was detected by polymerase chain...
reaction (PCR) analysis. Moreover, the aqueous humor showed a high expression of WT1 mRNA. The present findings demonstrate that reveals the chimeric BCR/ABL gene by PCR and detects WT1 mRNA in the aqueous humor.

2. Case presentation

The medical records of a patient with intraocular infiltration with acute lymphoblastic leukemia were retrospectively reviewed. The present study protocol was approved by the Ethics Committee of the Sapporo Medical University Hospital and conducted in accordance with the Declaration of Helsinki. After a full explanation of the purpose and protocol for this study, patient has provided informed consent for publication of the case.

2.1. Case

Our patient was a 40-year-old man who had developed systemic pain. He had initially visited another hospital 14 months earlier and had been diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). At that time, he underwent chemotherapy and bone marrow transplantation and achieved complete remission. However, a month after termination of the chemotherapy, he developed blurred vision in his right eye.

The initial ophthalmic examination disclosed a best-corrected visual acuity (BCVA) of 8/200 in the right eye and 20/12.5 in the left eye. The intraocular pressure (IOP) was 45mmHg in the right eye and 14mmHg in the left. A slit-lamp examination demonstrated conjunctival injection, corneal oedema, and hypopyon in the right eye. An ophthalmological examination of his left eye was unremarkable. Results of the laboratory investigations of serum including antinuclear antibodies, anti-double stranded DNA antibodies, rheumatoid factors, and antineutrophil cytoplasmic antibodies were unremarkable. Peripheral blood cell counts were normal. Topical betamethasone and anti-glaucoma medication were applied resulting in normalized IOP to 10mmHg and improved BCVA to 20/12.5 in his right eye a week later. There was no abnormality in his right eye fundus. Three months following the initial presentation, his right eye developed severe vision loss and ocular pain. Upon examination, the eye showed conjunctival injection, corneal edema, blood-streaked hypopyon, a shallow chamber, and extensive retinal detachment (Figs. 1 and 2). Brain magnetic resonance imaging (MRI) showed a massive high signal lesion in his right eye (Fig. 3). The BCVA was 16/200 and IOP was 30 mmHg. Intravenous methylprednisolone, antibiotics, and mannitol were applied with poor response.

The aqueous humor from his right eye was collected. A multiplex PCR/broad-range PCR was applied to screen the pathogen causing the infection.[4] There were no detection of herpes virus species, bacteria, fungi, toxoplasma, toxascaris, or any other pathogens. Next, the chimeric BCR/ABL1 mRNA and the expression of WT1 mRNA were examined, the details of which are described in the Methods section below.

2.1.1. Detection of major BCR/ABL1 mRNA and WT1 mRNA.

The anterior aqueous humor collected from the patient was centrifuged at 2000 × g for 5 minutes to harvest cells. RNA was extracted using the RNeasy Micro Kit (Qiagen GmbH, Hilden, Germany). The RNA concentration was measured using a Qubit 3.0 Fluorometer (Thermo Fisher Scientific, Waltham, MA).
Ocular manifestation is commonly diagnosed with blood tests during the remission period with normal blood cell counts. In most of these cases, ocular involvement developed coincidentally, in most of these cases, ocular involvement developed coincidentally, indicating intraocular involvement of Ph+ALL. In our case, extensive retinal detachment with high signal lesion was observed. This suggests the possibility that massive leukemic cells were infiltrated into the subretinal space.

The causes of hypopyon vary and include infection, autoimmune diseases, and malignant diseases. The clinical manifestations are similar in resemblance among these causes and it is often difficult to distinguish them solely by ophthalmic examination. The hypopyon is the accumulation of infiltrated inflammatory cells in cases of infection and autoimmune disorders. The intraocular involvement of malignant disease is called masquerade syndrome that resembles uveitis but is resistant to corticosteroid therapy. Intraocular infiltration of malignant diseases is thought to occur through direct infiltration of neoplastic cells, hemorrhage, or by ischemic changes. The phenotype of masquerade syndrome by malignant disease is usually uveitis like but occasionally other phenotypes such as retinal detachment and choroidal thickness are involved. In our case, extensive retinal detachment with high signal lesion in MRI was observed. This suggests the possibility that massive leukemic cells were infiltrated into the subretinal space.

The cause of malignant masquerade syndrome in adults is most often malignant lymphoma and leukemia and, more rarely, metastasis of cancer. It has been reported that 0.2% to 2% of leukemia patients develop leukemic infiltration such as hypopyon in the anterior segment of the eye. The etiology of ocular manifestation in leukemia patient is either opportunistic infection following immunosuppressive conditions caused by chemotherapy or leukemic cells infiltration. An accurate diagnosis is essential for precise treatment. In our case, no infectious pathogen was detected by PCR methods. There are several reports indicating intraocular involvement of Ph+ALL. Interest-ingly, in most of these cases, ocular involvement developed during the remission period with normal blood cell counts. Ocular manifestation is commonly diagnosed with blood tests.

### 3. Discussion

In this report, we described a case of leukemic intraocular infiltration developing during the period when the patient was believed to be in remission. The ocular manifestation started as unilateral hypopyon that temporarily responded to topical corticosteroid application. It then extended to intraocular infiltration with retinal detachment without hematological relapse. The molecular biological examination of the aqueous humor resulted in the diagnosis of Ph+ALL relapse. The ocular manifestation was solely resolved with molecular targeted therapeutics.

The causes of hypopyon vary and include infection, autoimmune diseases, and malignant diseases. The clinical manifestations are similar in resemblance among these causes and it is often difficult to distinguish them solely by ophthalmic examination. The hypopyon is the accumulation of infiltrated inflammatory cells in cases of infection and autoimmune disorders. The intraocular involvement of malignant disease is called masquerade syndrome that resembles uveitis but is resistant to corticosteroid therapy. Intraocular infiltration of malignant diseases is thought to occur through direct infiltration of neoplastic cells, hemorrhage, or by ischemic changes. The phenotype of masquerade syndrome by malignant disease is usually uveitis like but occasionally other phenotypes such as retinal detachment and choroidal thickness are involved. In our case, extensive retinal detachment with high signal lesion in MRI was observed. This suggests the possibility that massive leukemic cells were infiltrated into the subretinal space.

The cause of malignant masquerade syndrome in adults is most often malignant lymphoma and leukemia and, more rarely, metastasis of cancer. It has been reported that 0.2% to 2% of leukemia patients develop leukemic infiltration such as hypopyon in the anterior segment of the eye. The etiology of ocular manifestation in leukemia patient is either opportunistic infection following immunosuppressive conditions caused by chemotherapy or leukemic cells infiltration. An accurate diagnosis is essential for precise treatment. In our case, no infectious pathogen was detected by PCR methods. There are several reports indicating intraocular involvement of Ph+ALL. Interest-ingly, in most of these cases, ocular involvement developed during the remission period with normal blood cell counts. Ocular manifestation is commonly diagnosed with blood tests.

### Table 1

| Primer sequences for detecting major BCR-ABL1 and WT1. |
|---------------------------------|
| Target gene                     | Forward primer       | Reverse primer       |
|---------------------------------|----------------------|----------------------|
| Major BCR-ABL1 (outer primer)   | 5’-GGCCCATGTTACCGAGGATG-3’ | 5’-GGCCCATGTTACCGAGGATG-3’ |
| Major BCR-ABL1 (inner primer)   | 5’-GGAGGCATTGAGGCTGAGAAGGTG-3’ | 5’-GGAGGCATTGAGGCTGAGAAGGTG-3’ |
| β-actin                         | 5’-GGAGGTACACTCCAGGCTGAGAAGGTG-3’ | 5’-GGAGGTACACTCCAGGCTGAGAAGGTG-3’ |
| WT1                             | 5’-GGAGGTACACTCCAGGCTGAGAAGGTG-3’ | 5’-GGAGGTACACTCCAGGCTGAGAAGGTG-3’ |
| GAPDH                           | 5’-GGAGGTACACTCCAGGCTGAGAAGGTG-3’ | 5’-GGAGGTACACTCCAGGCTGAGAAGGTG-3’ |

WT1 = Wilms tumor gene.

β-actin and GAPDH were used as endogenous controls for major BCR-ABL1 and WT1, respectively.
and characteristic ophthalmic findings. However, when the hematological analysis of blood or bone marrow shows less systemic abnormality, intraocular fluid cytology is required. Although topical corticosteroids were not fully effective to hypopyon in our case, there were no other systemic findings. Our oncologist remained uncertain that hypopyon was the sign of relapse until the results of the molecular analysis of the aqueous humor.

There are a few reports in which FISH (fluorescence in situ hybridization) was conducted to detect the BCR/ABL fusion gene in the aqueous humor.\[16\]–\[18\] Although FISH is a popular method to confirm the presence of the chimera gene, it requires a certain amount of cells and false positives can occur through overlap. Therefore, we decided to perform PCR, and were able to determine the BCR/ABL fusion gene consistent with the diagnosis of Ph+ALL. The eye is a small organ, and there are few tissues and samples, including intraocular fluid, that are safe to procure for examination. The PCR method is beneficial for small sample volumes and rapidity in noting results. Similar to our case, when there is no evidence of leukemia in the blood, molecular biological examination of intraocular fluid is favorable. These results led us to perform a bone marrow examination and ultimately, we were able to confirm relapse. There are several additional reports in which ocular involvement was the single sign of leukemic relapse, similar to our case.\[10,15,16,18\]–\[21\]

The WT1 gene was initially identified as a tumor suppressor gene, and the mutation of the gene led to the development of pediatric renal tumors. It was then determined that WT1 was overexpressed in the majority of acute meloid leukemia (AML) and ALL cases.\[22\] Additionally, the increase of WT1 expression was concomitant to the progression of chronic myeloid leukemia (CML) and myelodysplastic syndromes (MDS).\[3,23,24\] The expression level reflects the activity of leukemia that is independent from chimiric DNA. WT1 is thought to be one of the markers for leukemia, and that can be used for predicting prognosis and monitoring relapse. Recently, WT1 peptide vaccination have demonstrated positive survival efficacy on leukemia patients.\[25\]–\[27\] We have examined WT1 mRNA expression of the aqueous humor. Surprisingly, the expression was much higher than that of bone marrow during the same period, 2.9 × 10^5 copies/μg and 7.1 copies/μg of RNA respectively. It was also undetactable in the control aqueous humor. These results suggest that monitoring WT1 expression in intraocular fluid can be a good candidate marker to screen leukemic infiltration in the eye regardless of leukemia subtype. In addition, it appears that the extent of WT1 expression in the eye reflects the leukemic infiltration severity even under silent phenotypic general conditions.

The present findings suggest the importance of prompt diagnosis of leukemic infiltration in the eye using molecular biological techniques. Furthermore, it raises the possibility of WT1 expression as the marker for topical leukemia relapse.

Author contributions

Conceptualization: Miki Hiraoka.
Data curation: Miki Hiraoka, Hiroshi Ikeda, Daisuke Furuya.
Formal analysis: Daisuke Furuya.
Investigation: Miki Hiraoka, Hiroshi Ikeda.
Methodology: Daisuke Furuya.
Project administration: Satoshi Takahashi.
Resources: Miki Hiraoka.
Supervision: Hiroshi Ohguro.
Writing – original draft: Miki Hiraoka.
Writing – review & editing: Hiroshi Ikeda, Daisuke Furuya, Satoshi Takahashi.
Miki Hiraoka orcid: 0000-0002-6411-2269.
Hiroshi Ohguro orcid: 0000-0003-1052-0280.

References

[1] Rothova A, Oojman F, Kerkhoff F, et al. Uveitis masquerade syndromes. Ophthalmoology 2001;108:836–99.
[2] Rosenthal AR. Ocular manifestations of leukemia. A review. Ophthalmology 1983;90:899–905.
[3] Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994;84:3071–9.
[4] Sugita S, Ogawa M, Shimizu N, et al. Use of a comprehensive polymerase chain reaction system for diagnosis of ocular infectious diseases. Ophthalmology 2013;120:1761–8.

[5] Furuya D, Moriai M, Kozumi Y, et al. Analysis of major BCR-ABL1 mRNA by digital polymerase chain reaction is useful for prediction of international scale. Int J Clin Oncol 2019;24:871–5.

[6] Ramsay A, Lightman S. Hypopyon uveitis. Surv Ophthalmol 2001;46:1–8.

[7] Ayliffe W, Foster CS, Marcoux P, et al. Relapsing acute myeloid leukemia manifesting as hypopyon uveitis. Am J Ophthalmol 1995;119:361–4.

[8] Ridgeway EW, Jaffe N, Walton DS. Leukemic ophthalmopathy in children. Cancer 1976;38:1744–9.

[9] Kincaid MC, Green WR. Ocular and orbital involvement in leukemia. Surv Ophthalmol 1983;27:211–32.

[10] Bunin N, Rivera G, Goode F, et al. Ocular relapse in the anterior chamber in childhood acute lymphoblastic leukemia. J Clin Oncol 1987;5:299–303.

[11] Schachar AP, Markowitz JA, Gayer DR, et al. Ophthalmic manifestations of leukemia. Arch Ophthalmol 1989;107:697–700.

[12] Novakovic P, Kellie SJ, Taylor D. Childhood leukaemia: relapse in the anterior segment of the eyes. Br J Ophthalmol 1989;73:354–9.

[13] Kim J, Chang W, Saghon M. Bilateral serous retinal detachment as a presenting sign of acute lymphoblastic leukemia. Korean J Ophthalmol 2010;24:245–8.

[14] Yoshida A, Kawan Y, Eto T, et al. Serum retinal detachment in an elderly patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia. Am J Ophthalmol 2003;139:348–9.

[15] Yi DH, Rashid S, Cibas ES, et al. Acute unilateral leukemia hypopyon in an adult with relapsing acute lymphoblastic leukemia. Am J Ophthalmol 2003;139:719–21.

[16] Hurtado-Sarrió M, Duch-Samper A, Taboada-Esteve J, et al. Anterior chamber infiltration in a patient with Ph+ acute lymphoblastic leukemia in remission with imatinib. Am J Ophthalmol 2005;139:723–4.

[17] Lee MH, Park MY, Lee JW. Leukemic glaucoma in a patient with chronic myeloid leukemia treated by intracameral methotrexate. Jpn J Ophthalmol 2010;54:362–4.

[18] Gulati R, Alkhabiry Y, Donthreddy V, et al. Isolated ocular manifestation of relapsed chronic myelogenous leukemia presenting as myeloid blast crisis in a patient on imatinib therapy: a case report and review of the literature. Case Rep Pathol 2015;2015:1–7.

[19] Patel AV, Miller JR, Nath R, et al. Unilateral eye findings: a rare herald of acute leukemia. Ocul Oncol Pathol 2016;2:166–70.

[20] Wadhwia N, Vohra R, Shrey D, et al. Unilateral hypopyon in a child as a first and sole presentation in relapsing acute lymphoblastic leukemia. Indian J Ophthalmol 2007;55:223–4.

[21] MacLean H, Clarke MP, Strong NP, et al. Primary ocular relapse in acute lymphoblastic leukemia. Eye (Lond) 1996;10:719–22.

[22] Menssen HD, Renkl HJ, Rodeck U, et al. Presence of Wilms’ tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995;9:1060–7.

[23] Tamaki H, Ogawa H, Ohyashiki K, et al. The Wilms’ tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 1999;13:393–9.

[24] Ogawa H, Ikegama K, Kawakami M, et al. WT1 gene transcript assay for relapse in acute leukemia after transplantation. Leuk Lymphoma 2004;45:1747–53.

[25] Maslak PG, Dao T, Bernal Y, et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galintepimut-S) in acute myeloid leukemia. Blood Adv 2018;2:2224–34.

[26] Di Stasi A, Jimenez AM, Minagawa K, et al. Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies. Front Immunol 2015;6:1–6.

[27] Tsuboi A, Oka Y, Kyo T, et al. Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease. Leukemia 2012;26:1410–3.